本帖最后由 老马 于 2013-3-13 13:43 编辑 ! p5 [* s$ G1 d
4 _, `7 g$ |- L. A% A健择（吉西他滨）+顺铂+阿瓦斯汀7 ~0 T \6 N" L* p6 H& o3 l) x8 ~
Gemzar +Cisplatin + Avastin
4 G9 o/ s' R2 h+ g9 ?# m9 Bhttp://annonc.oxfordjournals.org/content/21/9/1804.full! W9 z0 b5 \- u+ e& f
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
, p: K6 s3 W4 U: L+ ePatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 1 i8 ?) N. y2 Y( @( @2 m* a
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. $ D1 X: X }, y' [, {/ T! Z( t
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 848)
+ X/ [: P6 C- c" a3 g( b
华为网盘附件：! ~4 n& J' A' q. O$ M# O4 z# \
【华为网盘】ava.JPG$ b& T7 K5 g0 Z1 s) W
|
显身卡
